Norelgestromin
Pharmaceutical drug / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Norelgestromin?
Summarize this article for a 10 year old
Norelgestromin, or norelgestromine, sold under the brand names Evra and Ortho Evra among others, is a progestin medication which is used as a method of birth control for women.[5][6][7] The medication is available in combination with an estrogen and is not available alone.[5] It is used as a patch that is applied to the skin.[6][7]
Clinical data | |
---|---|
Trade names | Evra, Ortho Evra, Xulane, others |
Other names | Norelgestromine; NGMN; RWJ-10553; Levonorgestrel 3-oxime; 17β-Deacetylnorgestimate; 17α-Ethynyl-18-methyl-19-nortestosterone 3-oxime; 17α-Ethynyl-18-methylestr-4-en-17β-ol-3-one 3-oxime |
AHFS/Drugs.com | International Drug Names |
MedlinePlus | a602006 |
License data | |
Routes of administration | Transdermal patch |
Drug class | Progestogen; Progestin |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 99% (to albumin but not to SHBGTooltip sex hormone-binding globulin)[1][2][3] |
Metabolism | Liver (oxime to ketone reaction, hydroxylation, conjugation)[4] |
Metabolites | • Levonorgestrel[4] |
Elimination half-life | 17–37 hours[1][3] |
Excretion | Urine and feces[4] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.170.714 |
Chemical and physical data | |
Formula | C21H29NO2 |
Molar mass | 327.468 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Side effects of the combination of an estrogen and norelgestromin include menstrual irregularities, headaches, nausea, abdominal pain, breast tenderness, mood changes, and others.[4] Norelgestromin is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone.[8][9] It has very weak androgenic activity and no other important hormonal activity.[8][9]
Norelgestromin was introduced for medical use in 2002.[10] It is sometimes referred to as a "third-generation" progestin.[11][12] Norelgestromin is marketed widely throughout the world.[5] It is available as a generic medication.[13]